Table 2. Comparison of patient characteristics and laboratory data of the study population randomly divided to the development and internal validation cohorts.
| Baseline characteristics | All | Development | Internal Validation | p-value |
|---|---|---|---|---|
| N | 2,739 | 2000 | 739 | |
| Sex (Male) (%) | 1,570 (57.3) | 1153 (57.7) | 417(56.4) | 0.57 |
| Age (years) | 80 (77, 83) | 80 (77, 83) | 80 (77, 83) | 0.32 |
| BMI (kg/m2) | 21.8±3.9 | 21.9±4.0 | 21.8±3.6 | 0.90 |
| Primary kidney disease | ||||
| DKD (%) | 1,092(39.9) | 811(40.6) | 281(38.9) | 0.24 |
| Laboratory data | ||||
| UN (mg/dl) | 86.4±30.4 | 86.8±30.2 | 85.6±31.0 | 0.37 |
| Cr (mg/dl) | 7.3±2.9 | 7.3±2.9 | 7.3±2.8 | 0.49 |
| Albumin (g/dL) | 3.2±0.6 | 3.2±0.6 | 3.2±0.6 | 0.76 |
| Ca (mg/dl) | 7.9±1.0 | 8.0±1.1 | 8.0±1.1 | 0.18 |
| Pi (mg/dl) | 5.3±1.6 | 5.3±1.6 | 5.3±1.6 | 0.55 |
| CRP (mg/dl) | 0.46 (0.1, 2.1) | 0.46 (0.1, 2.08) | 0.46 (0.1, 2.38) | 0.36 |
| Hb (g/dl) | 8.4±1.5 | 8.3±1.5 | 8.4±1.4 | 0.18 |
| Absence of AVF(%) | 1,274(46.5) | 928(46.4) | 346(46.8) | 0.86 |
| Comorbidities | ||||
| CVD (%) | 255 (9.3) | 192 (9.6) | 63 (8.5) | 0.42 |
| Cancer (%) | 196 (7.2) | 146 (7.3) | 50 (6.8) | 0.68 |
| Dementia (%) | 453 (16.5) | 342 (17.1) | 111 (15.0) | 0.20 |
| Death<1 year(%) | 424 (15.5) | 313(15.7) | 111(15.0) | 0.72 |